REPLIGEN CORP Foreign Currency Transaction Gain (Loss), before Tax
REPLIGEN CORP (RGEN) reported Foreign Currency Transaction Gain (Loss), before Tax of $119.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-07-29
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $157.00K, a 96.12% decline year-over-year.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$38.00K, a 100.46% decline year-over-year.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $571.00K.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $190.00K.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for fiscal 2025 was $13.01M.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for fiscal 2024 was $0.00.
- REPLIGEN CORP foreign currency transaction gain (loss), before tax for fiscal 2023 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $119.00K 10-Q · filed 2026-07-29 | $690.00K derived: sum of 3 quarters · filed 2026-07-29 | $880.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$38.00K 10-Q · filed 2026-05-06 | $533.00K derived: sum of 2 quarters · filed 2026-05-06 | $723.00K derived: sum of 3 quarters · filed 2026-05-06 | $4.77M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $571.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $761.00K derived: sum of 2 quarters · filed 2026-02-26 | $4.81M derived: sum of 3 quarters · filed 2026-07-29 | $13.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.24M derived: sum of 2 quarters · filed 2026-07-29 | $12.44M 10-Q · filed 2025-11-04 | $12.44M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $12.25M 10-Q · filed 2026-07-29 | $12.25M derived: sum of 3 quarters · filed 2026-07-29 | $12.25M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $8.21M 10-Q · filed 2026-05-06 | $8.21M derived: sum of 2 quarters · filed 2026-05-06 | $8.21M derived: sum of 3 quarters · filed 2026-05-06 | $8.21M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |